Innovent Biologics

Pharma News for Novartis, Iovance, Certa, Innovent

Feb 20, 2024

FDA Approves Xolair for Food Allergies; FDA Accelerated Approval for Iovance’s AMTAGVI; Astellas and Kelonia Enter into Research and License Agreement; Fast Track Designation to Certa’s FT011; Innovent Announces Phase 3 Clinical Trial Updates for IBI311; Orphan Drug Designation to Cardiol’s Pericarditis Drug Candidate

Pharma News for Cytokinetics, Chiesi, AstraZeneca, Zevra

Jan 02, 2024

Cytokinetics Announces Results From SEQUOIA-HCM Clinical Trial of Aficamten; FDA Approves Chiesi’s FILSUVEZ Topical Gel; Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform; AstraZeneca to Acquire Gracell; Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application; Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362)

recent-pharma-news-and-updates-for-az-alkermes-innovent-lillys-avenue

Oct 13, 2020

US/AZ deal; Alkermes’ Schizophrenia drug; Innovent/Lilly’s China market expansion; Rejection for Avenue

pharma-news

Jun 11, 2020

AbbVie & Genmab’s Collaboration; Lilly’s antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent;

Wet Age-related macular degeneration treatment market

Feb 17, 2020

Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade

Gilead

Oct 25, 2018

Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives

transthyretin amyloidosis

Jan 19, 2018

Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper